Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

NCT03139981 is registered in ClinicalTrials.gov with Asana BioSciences as lead sponsor.

NCT NCT03139981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Lead sponsor
Asana BioSciences
Phase
Phase 1
Overall status
Completed
Start date
April 12, 2017
Completion date
December 5, 2017
Enrollment
36 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis eczema, dermatitis, atopic, dermatitis, eczematous